University of California

Eicosis, LLC

Carlos Antonio Tindade Da Silva

Ahmet Bora Inceoglu

Bruce D Hammock

Fawaz G Haj

Ahmed Bettaieb

Kin Sing Stephen Lee

Steven L Jinks

Kara Schmelzer

Carlos Antonio Trindade Da Silva

Buce D Hammock

Provided are compositions and methods for preventing, mitigating, decreasing, inhibiting and/or reversing bone loss and/or increasing and/or promoting bone regeneration and remodeling and/or preventing, mitigating, decreasing, inhibiting and/or reversing periodontitis and/or periodontal disease in a subject by administering to the subject an effective amount of an inhibitor of soluble epoxide hydrolase (sEH).

Methods of treating bone loss

Provided are methods and compositions for preventing, reducing, mitigating and treating pain, particularly neuropathic pain by the combined administration of an agent that increases EETs and an agent that reduces/inhibits endoplasmic reticulum (ER) stress.

Methods of inhibiting pain

The invention discloses a new series of inhibitors of soluble epoxide hydrolase (sEH) with improved physical properties that enhance their druglikeness to treat sEH associated diseases such as chronic diabetic neuropathic pain.

Potent soluble epdxide hydrolase inhibitors

The present invention provides methods and compositions for relieving pain and itching, of promoting wound healing, of reducing sickness behavior and of reducing inflammatory bowel disease or acne lesions in a subject by the topical administration of an inhibitor of soluble epoxide hydrolase, or of a cis-epoxyeicosatrienoic acid ('EET'), or by both.

Use of sEH inhibitors as analgesics

The invention discloses methods of using cis-epoxyeicosantrienoic acids ('EETs'), inhibitors of soluble epoxide hydrolase ('sEH'), or a combination of an EET and an inhibitor of sEH, to alleviate neuropathic pain in subjects suffering from such pain.

Alleviating neuropathic pain with EETs and sEH inhibitors

The invention relates to the discovery that cis-epoxyeicosatraenoic acids (EETs) bind to and act as agonists of peripheral benzodiazepine receptor and the cannabinoid CBreceptor. The invention provides methods of reducing symptoms of conditions whose activity is mediated by these receptors, including inhibiting anxiety, inhibiting the growth of cancer cells expressing peripheral benzodiazepine receptors, and reducing oxygen radical damage to cells, by contacting the cells with a cis-epoxyeicosantrienoic acid, an inhibitor of soluble epoxide hydrolase (sEH), or both. The invention further provides methods of inhibiting irritable bowel syndrome by administering to individuals with inhibiting irritable bowel syndrome a cis-epoxyeicosantrienoic acid, an inhibitor of soluble epoxide hydrolase (sEH), or both. In some embodiments, the method comprises administering to the individual a nucleic acid which inhibits expression of sEH.

Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors

The invention relates to methods, compositions, and uses of those compositions for making medicaments, for potentiating the beneficial effects of inhibitors of COX-1, COX-2, and 5-LOX, and reducing adverse effects, by also administering inhibitors of soluble epoxide hydrolase ('sEH'), with or without also administering one or more cis-epoxyeicosantrienoic acids. The invention further relates to the use of inhibitors of sEH as analgesics and to methods and compositions of epoxides of eicosapentaenoic acid and docosahexaenoic acid, optionally with an inhibitor of sEH, to reduce pain or inflammation or both.

Growing community of inventors

Davis, CA, United States of America

Ahmet Bora Inceoglu